Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome
PaperCitations, authors & open-access status
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 34 citations, 2020 year and closed oa status.
34
Citations
2020
Year
closed
OA Status